The Hydration Pharmaceuticals Company (HPC) fair value: what the stock is really worth
As of Nov 3, 2026: fair value (intrinsic value) of The Hydration Pharmaceuticals Company stock A$0.00, price A$0.00, upside +18.0%, quality 41 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
59‑month range A$0.0020 – A$0.3550 · fair‑value band A$0.0024 – A$0.0026 · the A$0.0020 price screens below the A$0.0024 fair value. As of Nov 4, 2026.
Follow The Hydration Pharmaceuticals in your weekly email
Every Wednesday you see whether The Hydration Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
The Hydration Pharmaceuticals Company Limited, together with its subsidiaries, markets and sells a range of liquid, tablet, and powder healthy hydration products in Australia, Canada, and the United States. It sells its products under the Hydralyte brand through retail stores and online.
Show moreShow less
The company was founded in 2001 and is based in Melbourne, Australia.
Stock analysis
The Hydration Pharmaceuticals Company (HPC) currently trades at A$0.0020, while our model-based Fair Value estimate is A$0.0024, implying the stock looks roughly 15.3% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: A$0.0024 (bear) to A$0.0026 (bull), the price of A$0.0020 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Consumer Defensive sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
The Hydration Pharmaceuticals Company reported revenue of $2.6M in FY2025 versus $6.1M in FY2021, a compound −19.6%/yr. Reported net income was −$3.0M in FY2025.
Key figures
Market cap A$1.1M (≈ $751K) Micro · P/S ratio 0.50 · EPS (TTM) A$−0.0100 · Net margin −116% · Return on equity −147% · Return on assets (EBIT) −97.0% · Operating margin −102% · Revenue (TTM) A$2.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 75% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −7% fair-value upside, at 18%, HPC screens cheaper than that median.
Fair Value models
BearA$0.0024Fair Value A$0.0024BullA$0.0026
Price A$0.0020 · Upside +18.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.3%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−87.2% (2020) → −127.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare The Hydration Pharmaceuticals Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Food Distribution · 85 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside+18.0% · Above median
Profitability
Return on assets−134.9% · Bottom 25%
Net margin (12 months)−115.4% · Bottom 25%
Operating margin (12 months)−102.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−21.1% · Bottom 25%
Valuation Multiplesvs Food Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "The Hydration Pharmaceuticals Company Fair Value". https://www.fairvalue-calculator.com/stock/HPC
Frequently asked questions
Is The Hydration Pharmaceuticals Company (HPC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of A$0.0024 versus a price of A$0.0020, about +18% upside (undervalued).
What is the fair value of HPC?
Our model-based fair value for The Hydration Pharmaceuticals Company is A$0.0024 (as of Nov 4, 2026), built from audited fundamentals. The current price: A$0.0020.
What is the quality score of HPC?
The Hydration Pharmaceuticals Company has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for The Hydration Pharmaceuticals Company (HPC)?
Our model-based price target is the fair value of A$0.0024 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario A$0.0024, optimistic scenario A$0.0026. It is a calculation from audited fundamentals, not an analyst target.
What is the The Hydration Pharmaceuticals Company stock forecast for 2026?
Our models put fair value at A$0.0024, about +18% upside versus a price of A$0.0020 (undervalued). Cautious scenario A$0.0024, optimistic scenario A$0.0026. The calculation is refreshed regularly with new filings.
What is the revenue of The Hydration Pharmaceuticals Company (HPC)?
The Hydration Pharmaceuticals Company reported trailing-twelve-month revenue of about A$2.1M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of The Hydration Pharmaceuticals Company (HPC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For The Hydration Pharmaceuticals Company it is A$0.0024 per share (as of Nov 4, 2026), against a price of A$0.0020. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is The Hydration Pharmaceuticals Company stock overvalued or undervalued in 2026?
As of Nov 4, 2026, HPC trades below its calculated fair value: price A$0.0020, fair value A$0.0024, a gap of about +18% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HPC?
No. The price is what the market pays today (A$0.0020); the fair value is what the company's own numbers justify (A$0.0024). For The Hydration Pharmaceuticals Company the two are A$0.0004 per share apart. That gap is exactly why we show both numbers side by side.
How much is The Hydration Pharmaceuticals Company worth?
The market values The Hydration Pharmaceuticals Company at about A$1.1M (market capitalisation, as of Nov 4, 2026). Per share that is A$0.0020; our models calculate a fair value of A$0.0024 per share.
What do the bullish and bearish scenarios say about HPC?
Our models span a range for The Hydration Pharmaceuticals Company: cautious scenario A$0.0024, base A$0.0024, optimistic A$0.0026 per share (as of Nov 4, 2026, price A$0.0020). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of The Hydration Pharmaceuticals Company (HPC)?
Balance-sheet figures for The Hydration Pharmaceuticals Company (as of Nov 4, 2026): return on equity −147.4%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is HPC from its 52-week high?
The Hydration Pharmaceuticals Company trades at A$0.0020, about 75% below its 52-week high of A$0.0080 and at the low of A$0.0020 (as of Nov 3, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0024 is for.
Which stocks are comparable to The Hydration Pharmaceuticals Company?
From the same area (Consumer Defensive) we also value Sysco Corporation, US Foods Holding, Performance Food Group, Jerónimo Martins, SGPS, S.A, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is The Hydration Pharmaceuticals Company stock attractive at the current price?
The data as of Nov 4, 2026: price A$0.0020, calculated fair value A$0.0024 (+18%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HPC calculated?
We run The Hydration Pharmaceuticals Company through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0024, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. The Hydration Pharmaceuticals Company currently trades 15 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of The Hydration Pharmaceuticals Company (HPC)?
The closing price on Nov 3, 2026 was A$0.0020. Our model-based fair value is A$0.0024, about +18% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with The Hydration Pharmaceuticals Company right now?
The price is below even our cautious bear case (A$0.0024). The market is more pessimistic than our downside scenario. The models converge in a tight band (A$0.0024 to A$0.0026), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of The Hydration Pharmaceuticals Company
How large is the market capitalisation of The Hydration Pharmaceuticals Company (HPC)?
The market capitalisation of The Hydration Pharmaceuticals Company is A$1.1M (≈ $751K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of The Hydration Pharmaceuticals Company (HPC)?
The price-to-sales ratio of The Hydration Pharmaceuticals Company is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of The Hydration Pharmaceuticals Company (HPC)?
Earnings per share at The Hydration Pharmaceuticals Company are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of The Hydration Pharmaceuticals Company (HPC)?
The net margin of The Hydration Pharmaceuticals Company is −116% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of The Hydration Pharmaceuticals Company (HPC)?
The return on equity (ROE) of The Hydration Pharmaceuticals Company is −147% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of The Hydration Pharmaceuticals Company (HPC)?
On an EBIT basis the return on assets of The Hydration Pharmaceuticals Company is −97.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of The Hydration Pharmaceuticals Company (HPC)?
The operating margin of The Hydration Pharmaceuticals Company is −102% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at The Hydration Pharmaceuticals Company (HPC)?
Revenue at The Hydration Pharmaceuticals Company is growing −21.1% versus a year earlier (3y avg +38.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does The Hydration Pharmaceuticals Company (HPC) generate?
The free cash flow of The Hydration Pharmaceuticals Company is −A$3.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does The Hydration Pharmaceuticals Company (HPC) hold?
The Hydration Pharmaceuticals Company holds more cash than debt, A$1.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch The Hydration Pharmaceuticals Company in the live analysis
One click puts The Hydration Pharmaceuticals Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026